Related Experiment Video
Updated: Feb 18, 2026
05:15
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
Published on: February 10, 2022
4.3K
Virus like particles as a platform for cancer vaccine development
Hui Kian Ong1, Wen Siang Tan2,3, Kok Lian Ho1
1Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.
Peerj
|November 22, 2017
Summary
Virus-like particles (VLPs) are promising platforms for developing cancer vaccines due to their safety and ability to elicit strong immune responses. This review explores VLP advancements and challenges in cancer vaccine development.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Cancer remains a significant global health threat, necessitating novel preventive and therapeutic strategies.
- Traditional treatments have limitations, driving the search for innovative vaccine platforms.
- Virus-like particles (VLPs) have emerged as a promising approach for cancer vaccine development.
Purpose of the Study:
- To review the current progress in VLP-based cancer vaccine development.
- To discuss the advantages and potential drawbacks of using VLPs for cancer vaccines.
- To compare VLPs with extracellular vesicles as vaccine platforms.
Main Methods:
- Review of existing scientific literature on VLP technology and cancer vaccines.
- Analysis of VLP characteristics, including structure, antigen presentation, and immunogenicity.
- Comparative assessment of VLPs and extracellular vesicles in the context of cancer vaccine development.
Main Results:
- VLPs mimic native viruses, are non-infectious, and can be engineered to display tumor-specific antigens.
- VLPs effectively stimulate antigen-presenting cells, promoting robust humoral and cell-mediated immunity.
- VLPs demonstrate potential to overcome tumor microenvironment immunosuppression and enhance cytotoxic T-lymphocyte activity.
Conclusions:
- VLPs offer a versatile and potent platform for developing effective cancer vaccines.
- Further research is needed to address potential challenges and optimize VLP-based cancer vaccine strategies.
- Extracellular vesicles present an alternative, comparable platform for cancer vaccine development.
Related Concept Videos
01:30Cancer Vaccines
1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
01:51Mechanisms of Retrovirus-induced Cancers
7.0K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.0K
01:03Rous Sarcoma Virus (RSV) and Cancer
6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.5K
01:27Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K